GC
AKBA icon

Grimes & Company’s Akebia Therapeutics AKBA Stock Holding History

Grimes & Company’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$18.3K – 351
2024
Q1 		$18.3K Buy
+10,000
New +$16K ﹤0.01% 343

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Grimes & Company's AKBA Position: Q2 2024 in Review

Grimes & Company sold out of Akebia Therapeutics (AKBA) in Q2 2024, closing a stake of 10,000 shares — an estimated $18.3K sold.

Grimes & Company first reported a position in AKBA in Q1 2024 and held it in 1 quarter. The position peaked at $18.3K in Q1 2024. 103 funds tracked by Wall St. Rank hold AKBA as of Q2 2024.

  • Grimes & Company reported no remaining Akebia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Grimes & Company sold 10,000 Akebia Therapeutics shares in Q2 2024, an estimated $18.3K.
  • Grimes & Company first reported a position in Akebia Therapeutics in Q1 2024 and held it in 1 quarter.
  • Grimes & Company's Akebia Therapeutics position peaked at $18.3K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2024.

Based on Grimes & Company's 13F filing for Q2 2024, filed 22 Jul 2024.